Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.

Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.

Key reasons to become a member:

Meet new partners and end-users
Share your success stories
Benefit from unique advantages
Shape the future of Nanomedicine in europe
Promote and educate

Know more

ETPN strategic inputs

As a major pan-European industry-oriented initiative, the ETPN aims at strengthening Europe’s capabilities and competitiveness in the area of nanomedicine innovation. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe.

We have contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine.

Know more

ETPN support to innovation

Complementary to its strategic inputs as an ETP to shape and support public funding on the most promising areas of Nanomedicine, the ETPN has designed in 2014 unique technical infrastructures regrouped in a central instrument: the Nanomedicine Translation HUB.

These free of charge services support and accelerate the development of the best Nanomedicine projects from innovative design to clinical development.

Know more

Are you on the Nanomedicine map?

The NanoMed Map provides thorough insights into the nanomedicine community by showing all the actors of the ecosystem in Europe and beyond. It was initiated by NanoMed 2020, CSA project under FP7_Health.

See the map



Latest news

Watch the replay! ETPN & NanoVation Tx. Webinar on Next Generation LNP Technologies

Oct 7, 2024

The ETPN recently hosted a groundbreaking webinar in collaboration with NanoVation Therapeutics™, bringing together nearly 600 participants to explore the future of LNP technologies for nucleic acid delivery. Discover the insights from leading experts like Pieter Cullis and Dominik Witzigmann, and access the full replay to dive into cutting-edge discussions shaping the future of nanomedicine.

ETPN Endorses Joint Statement for an Ambitious FP10 to Boost European Nanomedicine Innovation

Jul 4, 2024

The European Technology Platform on Nanomedicine (ETPN) proudly endorses the Joint Statement for an Ambitious FP10, published by EARTO and Business Europe. Supported by 110 European organizations, this statement calls for a significant increase in the RD&I budget and emphasizes the importance of pan-European collaborative research. The ETPN highlights the critical role of continued investment in nanomedicine to support innovative diagnostics, treatments, and nano-enabled vaccines. Discover more about our commitment to fostering European nanotechnology in healthcare.